The WHO has widened its COVID-19 treatment pool by adding baricitinib, the drug first identified as a COVID-19 treatment by BenevolentAI, to the top of its treatment guideline.
BenevolentAI’s Board Director, Jackie Hunter, will give a talk on how we’re using artificial intelligence to enhance the search for disease-modifying treatments for ALS.
Join BenevolentAI’s VP Drug Discovery at the AI in Drug Discovery Xchange 2021 for a talk on AI-driven target identification in ulcerative colitis and our collaboration with AstraZeneca.
BenevolentAI’s Director of Drug Discovery, Andrea Taddei, joins the CCM Scientific Conference to discuss using AI to identify potential new targets for CCM.
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
